COVID-19 Vaccine Distribution and Herd Immunity to End Pandemic
Successful vaccine development and rollout will boost industry goodwill and reduce ESG risk, but we’re keeping our valuations steady.
In this first of three articles, we give our outlook for the COVID-19 vaccine market and distribution. Subsequent articles will cover coronavirus treatments and the prospects for the companies involved.
Following a year with more than 83 million cases and 1.8 million deaths reported globally due to COVID-19, 2021 begins with two newly authorized vaccines being distributed to high-priority populations in the United States and Europe. These mRNA vaccines from Pfizer/BioNTech (PFE)/(BNTX) and Moderna (MRNA) have set a high bar for efficacy and safety, and they appear poised to ramp up supply and dominate the U.S. market throughout the first half of the year, supporting a foundation for herd immunity in the U.S. by midyear. With additional support from Johnson & Johnson (JNJ), Novavax (NVAX), AstraZeneca (AZN), and Chinese and Russian vaccine programs, global herd immunity looks achievable by 2023.
Karen Andersen does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.